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mObjectives: Medication nonadherence is common for osteoporosis,
but its consequences have not beenwell described. This study aimed to
quantify the clinical and economic impacts of poor adherence and to
evaluate the potential cost-effectiveness of improving patient adher-
ence by using hypothetical behavioral interventions. Methods: A pre-
viously validated Markov microsimulation model was adapted to the
Irish setting to estimate lifetime costs and outcomes (fractures and
quality-adjusted life-year [QALY]) for three adherence scenarios: no
treatment, real-world adherence, and full adherence over 3 years. The
real-world scenario employed adherence and persistence data from
the Irish Health Services Executive-Primary Care Reimbursement Ser-
vices pharmacy claims database. We also investigated the cost-effec-
tiveness of hypothetical behavioral interventions to improve medica-
tion adherence (according to their cost and effect on adherence).
Results: The number of fractures prevented and the QALY gain ob-
tained at real-world adherence levels represented only 57% and 56% of
ubli
al So
doi:10.1016/j.jval.2012.02.001hose expected with full adherence, respectively. The costs per QALY
ained of real-world adherence and of full adherence compared with
o treatment were estimated at €11,834 and €6,341, respectively. An
ntervention to improve adherence by 25% would result in an incre-
ental cost-effectiveness ratio of €11,511 per QALY and €54,182 per
QALY, comparedwith real-world adherence, if the intervention cost an
additional €50 and €100 per year, respectively. Discussion: Poor adher-
ence with osteoporosis medications results in around a 50% reduction
in the potential benefits observed in clinical trials and a doubling of the
cost per QALY gained from these medications. Depending on their
costs and outcomes, programs to improve adherence have the poten-
tial to be an efficient use of resources.
Keywords: adherence, cost-effectiveness, intervention, osteoporosis,
persistence.
Copyright © 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The management of osteoporosis is becoming a major priority in
public health. At least one in threewomen older than 50 years, and
one in five men, will suffer an osteoporotic fracture in their re-
maining lifetime [1]. These fractures result in significantmorbidity
nd mortality and reduction in quality of life and pose consider-
ble costs to already stretched health care systems [2,3]. Figures
derived from the International Osteoporosis Foundation estimate
that approximately 300,000 people older than 50 years have osteo-
porosis in Ireland. This figure represents 25% of this population.
The results of an Irish Burden of Illness Study demonstrated that
fall-related injuries in the elderly cost the Irish health care system
approximately €402 million each year [4]. With an increasingly
elderly population and longer life expectancy, the burden is set to
increase.
Fortunately, an increasing number of pharmacological agents
have become available in the last 10 years for the treatment of low
bone mineral density (BMD). Numerous clinical trials and meta-
* Address correspondence to:Mickaël Hiligsmann, Department of P
Avenue de l’Hôpital 3, Bât. B23, 4000 Liège, Belgium.
E-mail: m.hiligsmann@ulg.ac.be.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.analyses have shown that antiosteoporosis medications and in
particular the oral bisphosphonates significantly reduce the risk of
both vertebral and nonvertebral fractures [5]. In addition, eco-
nomic analyses, typically based on efficacy estimates drawn from
clinical trials, have consistency shown these medications to be
cost-effective in a wide range of patient profiles for both primary
and secondary prevention [6,7].
Despite the availability of proven effective pharmacotherapy
for managing osteoporosis, studies are continuing to show that
postfracture treatment with antiosteoporotic medications re-
mains suboptimal [8,9]. Furthermore, in more recent years, the
issue of nonadherence with drug therapy, particularly in chronic
asymptomatic diseases such as osteoporosis, further compro-
mises the clinical and economic effects of the management of
these patients. Adherence to treatments in patients with osteopo-
rosis has been found to be suboptimal in several studies [10–12].
These studies have concluded that between 50% and 75% of pa-
tients who were initiated on antiosteoporotic medications have
discontinued their medications within 12 months of commence-
ment. Although it is well recognized that poor adherence reduces
c Health, Epidemiology and Health Economics, University of Liège,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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605V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 0 4 – 6 1 2the potential benefits of osteoporosis therapy, lowering gains in
BMD resulting in increased risk of fragility fractures [13], the clin-
ical and economic consequences at a population level have been
rarely studied [14,15]. A few studies carried out to date have how-
ver suggested potential important clinical and/or economic im-
lications of poor adherence to osteoporosis medications [16–19].
Adherence is influenced by health beliefs such as risk percep-
tion, perceived benefits and disadvantages of drugs, self-efficacy,
and stage of change and communication problems with physi-
cians [20]. Over recent years, behavioral interventions to improve
patient adherence have been developed [21,22]. Although their
effectiveness still requires further validation, educational pro-
grams and patient counseling by nurses may be effective in im-
proving patient adherence. New therapeutic options with longer
dosing regimens have also been recently available for the preven-
tion and treatment of osteoporosis that may, at least in principle,
further help to increase adherence. Under limited resources, it is
becoming increasingly important to examine how cost-effective
an intervention should be in order for it to be considered worth-
while. Using simulation modeling, which allowed us to capture
the long-term effects of medications, this study aimed to quantify
the clinical and economic effects of poor adherence with osteopo-
rosis medications in Ireland and to estimate the potential cost-
effectiveness of hypothetical interventions to improvemedication
adherence according to their cost and effect on adherence.
Methods
A published and validated Markov microsimulation model on the
natural history of osteoporosis was developed by Hiligsmann et al.
[23] and has been frequently used to assess the cost-effectiveness
of osteoporosis management in Belgium [18,24–28]. The model
was recently updated with a 6-month cycle length to estimate the
cost-effectiveness of denosumab [28]. We used this updated
model to assess the clinical and economic burden of poor adher-
ence from the Irish public health care perspective, that is, the
Health Services Executive (HSE). The model was programmed by
using the software TreeAge Pro 2011 (TreeAge Pro, Inc., William-
ston, MA).
The simulation model estimated fracture events, costs, and
quality-adjusted life-years (QALYs) for three adherence scenarios:
no treatment, real-world adherence, and full adherence. The “no-
treatment” scenario included no costs and no benefits of treat-
ment. The real-world scenario employed adherence and persis-
tence data from the Irish HSE-Primary Care Reimbursement
Services (HSE-PCRS) pharmacy claims database for all treatment-
naive patients older than 55 years who started osteoporosis med-
ications in Ireland between 2006 and 2009, and the full-adherence
scenario assumed that patients were fully adherent over 3 years.
Patients therefore received treatment in themodel for amaximum
of 3 years, because most clinical trials last only 3 years and adher-
ence data were collected over this period. The model simulated a
patient’s lifetime (i.e., until death or 100 years), however, to cap-
ture all relevant costs and consequences of fractures experienced
during the treatment period.
A description of the different components of the model is out-
lined in this section.Mostmodel data are included in Table 1.More
details can be found in Appendix 1 in Supplemental Materials
found at doi: 10.1016/j.jval.2012.02.001. Please also refer to previ-
usly published research [17,23] for limitations of the model and
an illustration on how the model integrates memory [23].
Model structure
Figure 1 provides an overview of the model. The model health
states are no fracture, death, hip fracture, clinical vertebral frac-
ture, wrist fracture, other fracture, and the corresponding post-fracture states. Postfracture states were created because some pa-
rameters (e.g., fracture disutility) were estimated over a 1-year
period [28]. All the patients, one at a time, began in the “no-frac-
ture” state and every 6 months had a probability of having a frac-
ture of the hip, clinical vertebrae, wrist, or other site or dying.
Patients in a fracture state can stay in the same fracture state if
they refracture, change to another fracture state, die, or change in
the next cycle to the postfracture state. Patients being in any post-
fracture state might have a new fracture (all fracture types are
possible), die, ormove to the “no-fracture” state. Tracker variables
were created to record the number of each fracture type and used
to adjust transition probabilities, costs, and utilities to reflect the
impact of prior fractures.
Fracture incidence and mortality rates
Analyses were assessed in patients receiving osteoporosis medi-
cations. In Ireland at present, there are no conditions attached for
the reimbursement of antiosteoporosis therapies. Unlike the
United Kingdom and other European countries, Ireland has access
to unlimited prescribing of these products. Therefore, clinicians
make their decision on whether or not to prescribe these products
on the basis of the results of densitometry and BMD levels, history
of fracture, risk factors, and so on. In this study, we assumed that
all treated patients have the same risk as patients with osteopo-
rosis, based on the definition of the World Health Organization
(i.e., BMD T score of2.5). All patientswere therefore assumed to
have the same base-case risk before treatment efficacy is im-
pacted.
To accurately reflect the risk of patients with a BMD T score of
2.5 in comparison with that of the general population, the risk
f fracture in the general population was adjusted by relative risk
RR) parameters, using a previously validatedmethod [30] (see Ap-
endix 1 for further details in Supplemental Materials found at
doi: 10.1016/j.jval.2012.02.001). The incidence of hip fractures in
the general population was derived from the Health Atlas Ireland,
for the year 2008 (http://www.hse.ie/eng/services/maps/). Because
the incidence of other fractures was not known, we assumed that
the age- and sex-specific ratio of index fracture to hip fracture in
Ireland was the same as found in Sweden [1]. This assumption,
used in the development of many FRAX models [36], appears to
hold true forWest European countries, theUnited States, andAus-
tralia [37].
Age-specific mortality rates are available from the Central Sta-
tistics office in Ireland, and excessmortalitywasmodeled after hip
and vertebral fractures [31]. Because excess mortality may be at-
tributable to comorbidities, we conservatively assumed that only
25% of the excess mortality following a hip or vertebral fracture
could be directly or indirectly attributable to the fractures them-
selves [38,39].
Fracture cost
The perspective of the public health care payer (i.e., the HSE) was
adopted for all cost estimates. Only direct medical costs were re-
ported. All costs were reported as 2008 values. Direct hip fracture
costs are divided into hospitalization cost (in the first cycle follow-
ing the fracture) and long-termcosts for patients being institution-
alized following the fracture. The hospitalization cost of hip frac-
ture was obtained from the Hospital In-Patient Enquiry system for
2008 and the associated Disease Related Group costs (http://
www.healthatlasireland.ie).
The cost of nursing homewas selected from the average cost of
approved private nursing homes in Dublin North East and Dublin
Mid Leinster (N 185) (requested from the HSE), and the probabil-
ity of admissions to a nursing home after a hip fracture was de-
rived from the study of Beringer et al. [32]. Of 2034 subjects (men
and women) living at home at the time of fracture, 10% were in
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tionalized later in life in any case, regardless of their hip fracture,
an adjustment wasmade to only include long-term costs attribut-
able to the fracture itself [23].
Nonhip fractures have been quantified relative to hip fracture
on the basis of their costs [33]. So, the costs of clinical vertebral,
rist and other fracture represent 17.4%, 14.5%, and 17.4% of the
Table 1 – Fracture incidence, costs, excess mortality, and u
Parameter Women
Incidence (annual rate/1000
persons-years)
Hip fracture 1.12 (60–64 y), 1.99 (65–69 y), 4.73 (
9.80 (75–79 y), 17.47 (80–84 y), 32
(85 y)
CV fracture 1.75 (60–64 y), 2.81 (65–69 y), 6.67 (
8.32 (75–79 y), 9.42 (80–84 y), 14.
(85 y)
Wrist fracture 3.28 (60–64 y), 4.42 (65–69 y), 7.75 (
7.73 (75–79 y), 9.78 (80–84 y), 12.
Other fracture* 2.55 (60–64 y), 4.98 (65–69 y), 6.77 (
13.07 (75–79 y), 15.40 (80–84 y), 3
(85 y)
Relative risk of fracture
attributable to
osteoporosis
Hip fracture 3.39 (60–69 y), 2.25 (70–79 y), 1.57 (
CV fracture 2.18 (60–69 y), 1.77 (70–79 y), 1.51 (
Wrist fracture 1.61 (60–69 y), 1.43 (70–79 y), 1.30 (
Other fracture 1.90 (60–69 y), 1.61 (70–79 y), 1.42 (
Excess mortality after hip and
clinical vertebral fracture
0–6 mo, 6–12 mo, subs year 4.53, 1.75, 1.78
Direct fracture costs (in €2008)
Hip, first 6 mo From 11,215 to 13,140
Hip, yearly long-term costs From 4,449 to 4,805
CV, first 6 mo From 1,950 to 2,285
Wrist, first 6 mo From 1,624 to 1,903
Other, first 6 mo From 1,947 to 2,281
Health states utility values
General population 0.83 (60–69 y), 0.77 (70–79 y), 0.72 (
Hip (first year/subs year)†
CV (first year/subs year)†
Wrist (first year/subs year)†
Other (first year/subs year)†
CV, clinical vertebral; subs, subsequent.
* Other fractures included humerus, tibia/fibula, pelvis, and ribs frac
† Relative reduction in health utility value (represents the proportion
No Fx 
Death 
Wrist Fx Other Fx 
CV Fx Hip Fx 
Post Other Post Wrist 
Post Hip Post CV 
Fig. 1 – Model structure. Transitions to death and from
postfracture states to any fracture states. “Death” and “No
Fx” were excluded from the graph for simplicity. CV,
clinical vertebral; FX, fracture.acute hip fracture cost, respectively. Nonhip fractures were con-
servatively assumed to be not associated with long-term costs.
Fracture disutility
Utility values for thegeneral populationaswell as relative reductions
due to fractures in the year following the fracture and in subsequent
years were derived from a recent systematic review, which sug-
gested reference values for countries that do not have their own da-
tabase [34]. Themodel took intoaccount that thenumberof fractures
is apredictor ofqualityof life. In thecaseof anoccurrenceof a second
fracture at the same site, the impact of the first fracture event was
reduced by 50%, as previously suggested [23]. For example, if a pa-
tient with a prior hip fracture suffered another hip fracture, the rel-
ative reductionof utility attributable to thefirst hip fracturewas then
0.95 and the total reduction of utility attributed to both fractureswas
therefore 0.76 (0.95 0.80) in the year following the fracture. For an
ndividual with both a hip fracture and a vertebral clinical fracture,
he total impact on QALYwas assumed to be equal to the sumof the
mpacts related to each of the fractures [26].
Drug therapy
Treated patients were assumed to receive the effectiveness of oral
values used in the model.
Men Reference
y), 0.62 (60–64 y), 1.51 (65–69 y), 2.02 (70–74 y),
5.68 (75–79 y), 10.69 (80–84 y), 20.01
(85 y)
[29]
y), 1.97 (60–64 y), 1.81 (65–69 y), 3.38 (70–74 y),
5.61 (75–79 y), 6.56 (80–84 y), 14.13
(85 y)
[1]
y),
 y)
1.22 (60–64 y), 2.11 (65–69 y), 0.60 (70–74 y),
1.59 (75–79 y), 1.82 (80–84 y), 3.82 (85 y)
[1]
y), 2.31 (60–64 y), 5.56 (65–69 y), 5.18 (70–74 y),
6.91 (75–79 y), 22.47 (80–84 y), 28.67
(85 y)
[1]
) 4.76 (60–69 y), 3.58 (70–79 y), 2.05 (80 y) [30]
) 2.65 (60–69 y), 2.39 (70–79 y), 1.93 (80 y) [30]
) 1.81 (60–69 y), 1.70 (70–79 y), 1.50 (80 y) [30]
) 2.23 (60–69 y), 2.05 (70–79 y), 1.73 (80 y) [30]
5.75, 2.31, 1.69 [31]
From 12,053 to 14,042 [29]
From 4,523 to 4,845 [31,32]
From 2,096 to 2,442 [33]
From 1,746 to 2,034 [33]
From 2,093 to 2,438 [33]
) 0.84 (60–69 y), 0.78 (70–79 y), 0.71 (80 y) [34]
0.80/0.90 [34]
0.72/0.93 [34,35]
0.94/1.00 [34,35]
0.91/1.00 [34]
.
ss of QALY due to the fracture).tility
70–74
.97
70–74
63
70–74
36 (85
70–74
5.10
80 y
80 y
80 y
80 y
80 y
turesbisphoshonates, the most widely prescribed antiosteoporosis
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607V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 0 4 – 6 1 2medications in Ireland and worldwide. The clinical effectiveness
of oral bisphosphonates in the treatment of womenwith osteopo-
rosis was derived from a recent meta-analysis conducted for the
National Institute for Health and Clinical Excellence appraisal and
included large randomized controlled trials on alendronate and
risedronate [40]. The RRs of fracture in the treatment group versus
he placebo group were 0.71 for hip fracture, 0.58 for clinical ver-
ebral fracture, and 0.78 forwrist and other fractures assuming the
R for other nonvertebral fracture. The effect of treatment was
ssumed to linearly decline to zero after stopping therapy, during
duration (called offset-time) equal to the duration of therapy, in
ine with clinical studies [41]. The mean annual drug cost for pa-
tients taking osteoporosismedications in Irelandwas estimated at
€422.3 for women and at €417.0 for men. The costs of the drugs are
taken from the HSE-PCRS. In this particular scheme, there is no
co-payment for the patients. Monitoring cost includes one yearly
physician visit (€65, HSE, http://www.hse.ie) and one bone densi-
ometry measurement every second year (estimated at €90, Irish
Osteoporosis Society, http://www.irishhealth.com/article.html?
id7099). Adverse events were not included in the analysis be-
cause randomized studies have not shown significant differences
between placebo and actively treated patients [5].
Medication adherence
Adherence data were obtained from the Irish HSE-PCRS database,
formerly the General Medical Services Payments Board scheme.
This scheme provides free health care to approximately 30% of the
Irish population (approximately 1.2 million). Eligibility for the
scheme is means tested for those younger than 70 years and is
confined to persons who are unable without undue hardship to
arrange general practitioner services for themselves and their de-
pendents. Patients registered under this scheme are dispensed all
medicines free of charge. From July 2001 to December 2008, the
service has been made available to all those older than 70 years.
While the HSE-PCRS population cannot be considered representa-
tive of the entire population, because the elderly and the socially
disadvantaged are overrepresented, it is estimated to account for
approximately 70% of all medicines dispensed in primary care.
National prescription files were analyzed for the years 2006–2009
to identify all prescription items relating to medicines dispensed
for the management of osteoporosis (Anatomical Therapeutic
Chemical classification system code M05B) in all patients aged 55
years and older. New users of antiosteoporosis medications were
defined as those not receiving any medication for osteoporosis in
the previous 12 months. The final adherence database included a
total of 70,669 women and 12,613 men, with the majority of these
aged older than 75 years.
Both persistence and adherence to treatment were measured
by using the pharmacy claims database. Persistence is defined as
“the duration of time from initiation to discontinuation of treat-
ment” [42]. Persistence was defined as a dichotomized variable
persistent or not) as to whether a patient continued therapy
eyond an elapsed time period. In this study, we vary the time
eriods (i.e., 6 months to 3 years) and a permissible gap of 9
eeks was selected in the base-case as monthly regimens were
ncluded in the database. In the subgroup of persistent patients,
dherence was calculated as the medication possession ratio
MPR), which is the ratio between the numbers of days of med-
cation supplied to the number of days in a time interval. Ad-
erence can be dichotomized (adherent or nonadherent) ac-
ording to the MPR. The conventional approach is to use a cutoff
f 0.8 [43], but this was varied in sensitivity analysis. Patients
ith a MPR greater than or equal to 0.8 were therefore consid-
red to be adherent, in the base-case analysis. The probability of
atients restarting therapy 1 year after stopping was also esti-
ated. All analyses were performed by using SAS (version 9.1,
AS Institute Inc., Cary, NC).In the model, patients were at risk of discontinuation within 3
years. For patients who stopped taking their therapy, the treatment
cost was stopped in the middle of the dropout cycle and the offset-
time period started at the same time. For those who discontinued
therapy within 6 months, no treatment effect was received [44], be-
causeat least 6monthsof treatment isnecessary to reduce the riskof
fractures [45,46].Themeandrugcostof thesepatients, administrated
in the first cycle of the model, was specifically estimated at €119.13
or women and at €97.40 formen (HSE-PCRS database). Patients who
iscontinued therapy can restart therapy after one cycle without
reatment. The maximum duration of treatment remains however
imited to 3 years from the start of the simulation.
Poorly adherent patients (MPR  0.8) suffer from a lower
reatment efficacy. Poor adherence was associated with a 17%
ncrease in fractures rates (RR  1.17; 95% confidence interval
CI] 1.09–1.25) [10]. The RRs from the NICE meta-analysis were
applicable to the population with adherence of 0.8 or greater.
So, for instance, if oral bisphosphonates was assumed to reduce
the risk of hip fracture by 29%, then adherent patients would
experience a 29% reduction in hip fracture while poorly adher-
ent patients would experience only a 17.1% (0.71  1.167 
0.829) reduction in hip fracture. Drug costs in the groups of
poorly and highly adherent patients were adjusted by the mean
MPR of the group. In the full-adherence scenario, drug cost was
equal to the MPR of the group of adherent patients (i.e., MPR 
0.8) (see Appendix 2, Table 3, in Supplemental Materials found
at doi: 10.1016/j.jval.2012.02.001). Adherent patients from the
real-world adherence scenario and patients from the full-ad-
herence scenario were therefore associated with the same drug
cost.
Analyses and simulation
Patients were stratified into groups according to sex (female/
male) and age (55–64, 65–69, 70–74, and 75 years). They en-
tered into the model at the age of 60, 67, 72, and 80 years for the
different age groups, respectively. First-order Monte-Carlo mi-
crosimulations (trials) were performed for each scenario, and
fractures, costs, and QALYs were recorded over 3 years and over
a patient’s lifetime. A single outcome’s value is the sum of the
outcomes (i.e., costs and QALYs) from the states traversed by an
individual. By simulating patients one by one, a microsimula-
tion model introduces variability between patients that can be
reduced by simulating a large number of patients. A total of
200,000 trials were deemed sufficient to guarantee the stability
of the results [28]. To enable variability analyses, each model
was run 10 times with 200,000 patients.
The potential loss of benefits resulting from poor adherence
was first estimated by comparing the outcomes (i.e., number of
fractures andQALYs) obtained at real-world adherence levelswith
those expected with full adherence. The number of fractures re-
sulting from poor adherence in patients from the adherence data-
base was then determined by multiplying the difference between
the lifetime number of fractures in the full and real-world adher-
ence scenarios by the number of patients included in the different
age and sex groups. The incremental cost-effectiveness ratio
(ICER) was calculated between the three adherence scenarios.
ICER is defined as the difference in terms of (lifetime) cost between
strategies divided by their difference in terms of (lifetime) effec-
tiveness (here measured as QALYs). An ICER represents the incre-
mental cost per one QALY gained. Mean ICER and the 95% CI were
calculated for each analysis. Future costs and health effects
(QALYs) were discounted by 4% annually according to the Irish
guideline for cost-effectiveness research [47].
Sensitivity analyses were performed to assess the impact of
assumptions on the results. These include changes in fracture
risk, cost and disutility, excess mortality, and assumptions on
medication adherence. In particular, other refill gaps and MPR
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cost-effectiveness of hypothetical adherence-enhancing inter-
ventions according to their cost (marginal and one-time costs) and
effect on adherence (improvements between 10% and 50% [21]).
Because interventions can be associated withmarginal (e.g., mon-
itoring) or one-time (e.g., education program) costs, both aspects
were investigated.
Results
Adherence data
In women, persistence rates were 64.3%, 52.7%, and 45.0% after 1,
2, and 3 years, respectively (Table 2). These values were 60.0%,
41.1%, and 29.4% in men. In the subgroup of persistent patients,
the probabilities of being highly adherent (MPR  0.8) were esti-
mated between 82.3% and 93.0%.
Results are sensitive to the refill gap length and to the MPR
threshold. So, for example, 56.8%, 64.3%, and 69.0% of women
were considered as persistent after 1 year using a 5-, 9-, and 13-
week refill gap, respectively. The probability of being highly adher-
ent (MPR greater than or equal to the threshold) was estimated on
average at 94.1%, 89.1%, and 75.7% assuming a threshold of 0.7, 0.8,
or 0.9 for high adherence, respectively.
Reinitiation rates at 1 year were 25.4% for women and 21.5% for
men, with a gap length of 9 weeks. These values were 42.1% and
34.9%, and 16.9% and 14.5% with refill gap periods of 5 and 13
weeks, respectively. Mean MPR in the group of adherent and non-
adherent patients ranged from 0.95 to 0.96 and from 0.47 to 0.70,
respectively.
Model validation
The model performed well during validation, producing fracture
incidence and mortality rates that were similar to the observed
data. Under the assumption of no treatment, absolute lifetime
risks of hip fracture and of any major osteoporotic fractures (hip,
vertebral, or wrist) were estimated, respectively, at 21.3% and
39.6% for a women aged 60 years with the fracture risk of the
average population, in the range of estimates reported in the lit-
erature [48]. Expected life expectancies were also very similar to
empirical data (differences of 0.1 year). Furthermore, tests on
odel parameters andmodeling assumptions (such as the effects
f changing the value of some parameters) were consistent with
xpected conclusions. Model-based projections of prescription
rug use were also validated. By using the model, we calculated
he percentage of patients on osteoporosis drug therapy at 3 years
including patients who have restarted therapy after stopping).
Table 2 – Persistence and adherence data in Irish women a
6 mo 1 y
Women
Nonpersistence 26.2% 35.7%
Poor adherence 13.1% 7.7%
High adherence 60.8% 56.6%
Number of persistent cases 52,192 42,819
Men
Nonpersistence 40.0% 51.8%
Poor adherence 10.0% 5.1%
High adherence 50.0% 43.2%
Number of persistent cases 7,569 5,557
* Refill gap period of 9 wk; medication possession ratio of 0.8 to dehese values were 52.5% and 35.6% for women and men, respec- ttively, consistent with estimates of 53.4% and 34.3%, respectively,
from the adherence database. To determine the number of simu-
lations, a varying number of trials (from 10,000 to 500,000) were
run 10 times and, as in the case of the Belgian version of themodel
[28], the distance between the upper and lower limits of the 95%
CIs of the ICER of osteoporosis medications compared with no
treatment reached a plateau from 200,000 trials.
Societal burden: base-case analysis
Themean lifetime number of hip fractures per patientwas 0.49 for
the no-treatment scenario, 0.47 for the real-world scenario, and
0.46 for the full-adherence scenario. The equivalent values for any
osteoporotic fractures were 1.32, 1.27, and 1.23, respectively
(Table 3). Therefore, the lifetime number of hip and all osteopo-
rotic fractures prevented in the case of real-world adherence rep-
resent 56.7% (95% CI 56.2%–57.3%) and 56.3% (95% CI 56.0%–56.7%)
to that estimated with full-adherence scenario, respectively (Fig.
2). The QALYs gain in the real-world adherence scenario was esti-
mated at 56.0% (95% CI 54.6%–57.5%) to that obtained under full-
adherence scenario. When assuming a 3-year time horizon, the
number of fractures and the QALYs gain obtained at real-world
adherence scenarios represent 65.7% (95% CI 65.9%–65.9%) and
65.4% (95% CI 64.0%–66.9%) to that estimated with the full-adher-
ence scenario, respectively.
Compared with no treatment, real-world adherence sce-
nario was associated with an additional lifetime cost of €266.3
and a 0.023 lifetime QALY gain, giving an ICER of €11,834 per
QALY gained (95% CI €11,197–€12,470), as illustrated in Table 3.
The full-adherence scenario was associated over lifetime with a
lower cost and a higher QALY than the real-world adherence
scenario, giving a negative ICER of €659 per QALY (95% CI
1488 to €171). Full adherence is said to be cost-saving com-
ared with real-world adherence.
For the 83,282 patients included in the database, the lifetime
umber of hip and of all osteoporotic types of fractures due to
edication nonadherence was estimated at 1271 (95% CI 1238–
304) and 3340 (95% CI 3295–3386), respectively. These fractures
esult in a QALY loss of 1470 (95% CI 1398–1544).
Societal burden: sensitivity analyses
As observed in Table 4, the percentage of QALY loss due to poor
adherence is substantially greater in men than in women. Other
analysis suggests that the burden of adherencewas primarily driven
by persistence. Full adherence was responsible for 4.5% [ (3340 
3191)/3340] of the number of fractures, and 7.8% {[(100  56.3) 
(100  59.7)]/(100  56.3)} of the QALY loss, attributable to poor ad-
erence. Definitions of nonadherence (i.e., refill gap period and MPR
en*.
Follow-up
1.5 y 2 y 2.5 y 3 y
41.9% 47.3% 51.9% 55.0%
5.9% 4.7% 4.1% 3.5%
52.2% 48.0% 43.9% 41.5%
35,925 30,051 24,983 20,781
58.9% 64.0% 68.1% 70.6%
3.4% 2.6% 2.3% 2.1%
37.7% 33.5% 29.6% 27.3%
4,246 3,323 2,567 1,991
igh compliance, 0.8 to define poor adherence.nd mhreshold) also had an impact on the results, while baseline fracture
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609V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 0 4 – 6 1 2risk and treatment efficacy markedly affected the number of frac-
tures attributable to poor adherence. Because more patients were
good adhererswhen assuming anMPR threshold of 0.7, this scenario
resulted in higher QALY gain and fractures prevented.
Potential adherence-enhancing interventions
Figure 3 presents the cost-effectiveness of potential adherence-
nhancing interventions according to their cost and effect on ad-
erence. So, for example, an intervention to improve adherence
nd persistence by 25% would result in an ICER of €11,511 per
QALY (95% CI €9,238–€13,784) and €54,182 per QALY if the inter-
ention cost an additional €50 and €100 per year, respectively. For
otential interventions associated with a 50% increase in adher-
nce rates, their cost-effectiveness was estimated at €26,999 per
ALY (95% CI €25,034–€28,965) and €56,195 per QALY (95% CI
Table 3 – Clinical and economic burden of poor adherence
3 y and over lifetime).
Follow-up Adherence
No treat
Patient cost over 3 y
Treatment cost 0 922
Disease cost 1,025 865
Total cost 1,025 1,787
Outcomes over 3 y
Hip fractures per patient 0.044 0
All fractures per patient 0.146 0
QALYs per patient 2.001 2
Patient cost over lifetime
Treatment cost 0 922
Total disease cost 11,425 10,769
Acute fracture cost 5,170 4,848
Long-term fracture cost 6,255 5,921
Total healthcare cost 11,425 11,691
Outcomes over lifetime
Hip fractures per patient 0.495 0
All fractures per patient 1.320 1
QALYs per patient 6.638 6
ICER (lifetime cost per lifetime QALY gained)
95% CI
Note. Total health care costs include treatment cost and disease costs
6 mo following the fracture) and long-term fracture cost.
CI, confidence interval; ICER, incremental cost-effectiveness ratio; QA
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Fig. 2 – Impact of medication adherence and persistence on
QALY) and on (treatment, disease, and total) costs. QALY, quality€52,084–€60,166) for additional annual costs of €100 and €150, re-
spectively. In other terms, a program to improve adherence and
persistence by 10%, 25%, or 50% would remain cost-effective at a
threshold of €45,000 per QALY if it cost a maximum of €119.4,
€299.0, and €726.3 annually per patient, respectively.
Discussion
Poor adherence undermines the potential effectiveness of osteopo-
rosis medications in preventing fractures. By using simulationmod-
eling, we estimated that approximately 50% of the expected benefits
of osteoporosis medications were lost because of nonadherence.
Moreover, poor adherence resulted in approximately a doubling of
the cost per QALY gained from thesemedications. Sensitivity analy-
osteoporosis medications: Base-case analysis (results at
ario Incremental values
Full RW vs no
treat
Full vs no
treat
Full vs RW
1,395 922 1395 473
780 160 245 85
2,175 762 1150 388
0.033 0.007 0.011 0.004
0.111 0.023 0.035 0.012
2.008 0.005 0.007 0.002
1,395 922 1395 473
10,284 656 1140 485
4,658 322 512 190
5,626 334 629 295
11,679 266 255 12
0.460 0.020 0.035 0.015
1.229 0.052 0.092 0.040
6.678 0.023 0.040 0.017
11,834 6341 659
11,197–12,470 5944–6739 1488 to 171
fracture-related cost), which consist of acute fracture cost (in the first
uality-adjusted life-year; RW, real-world; treat, treatment.
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610 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 0 4 – 6 1 2ses in linewith the results of otherpublishedstudies [49]have shown
that nonpersistence is the leading problem with adherence, with
more than 90% of the clinical burden of poor adherence resulting
from nonpersistence. We also investigated the economic value of
improving patient adherence by using a variety of hypothetical in-
terventions, and our results suggest a favorable ICER for themajority
of intervention effects and cost assumptions.
Studies in other countries have also shown that adherence
with osteoporosismedicationsmay have clinical and/or economic
implications [16–19], but they have rarely examined the impact of
both persistence and adherence on clinical and economic out-
comes. A similar analysis was conducted in Belgian women by
using a prior version of the same model [17]. This analysis sug-
gested that poor adherence with osteoporosis medications re-
duced the expected number of fractures and QALY gain by around
60%. The lower estimate in our studymay be explained partially by
longer refill gap length for persistence and reinitiation of patients
who discontinue therapy. Recent analyses have also suggested in
other settings that interventions to improve osteoporosis medica-
tion adherence will likely have favorable ICERs if their efficacy can
be sustained [17,50].
Strengths of this study include the large-scale prescribing da-
tabase that estimates persistence, adherence, and reinitiation
rates in both men and women with varying definitions for nonad-
herence (MPR threshold and gap lengths). We have also chosen a
validated Markov microsimulation [23] that has been frequently
used to assess the cost-effectiveness of osteoporosismanagement
[18,24–28]. Conservative assumptions were used and many sensi-
tivity analyses were performed to show the potential impact of
parameter assumptions and data on the results. National health
care registers were also used to collect data for the model such as
fracture incidence, fracture cost, and the cost of medications.
Our study also presents some important improvements in the
methodology to incorporate medication adherence and persis-
tence in modeling of osteoporosis that increase the accuracy and
reliability of the analysis. So, for the first time ever, patients can
restart therapy in the model after discontinuation; the cost of
highly and poorly adherent patients was related to the mean
MPR of the group and a specific cost was assumed for patients
who discontinued therapy prematurely. Moreover, patients
were at risk of discontinuation in half of every cycle and the
Table 4 – Sensitivity analyses on the clinical burden
(expressed in % of QALY gain* and in number of
osteoporotic fractures†) of poor adherence with
osteoporosis medications.
% of QALY
gain
Number of
fractures
Base-case analysis 56.3 (54.5–57.5) 3340 (3295–3386)
Women 57.6 (56.2–59.1) 2814 (2771–2856)
Men 44.7 (42.6–46.8) 527 (519–535)
5-wk refill gap 50.9 (49.1–52.7) 3779 (3741–3818)
13-wk refill gap 59.9 (58.2–61.6) 3062 (3033–3092)
Full compliance 59.7 (58.2–61.2) 3191 (3152–3229)
MPR of 90% 54.7 (53.3–56.1) 3612 (3579–3645)
MPR of 70% 58.0 (56.9–59.2) 3266 (3239–3294)
Treatment efficacy 20% 58.0 (56.9–59.1) 3985 (3952–4017)
Fracture risk 25% 54.5 (52.7–56.3) 4342 (4295–4388)
Fracture risk 25% 57.4 (56.1–58.5) 2405 (2,375–2,435)
MPR,medication possession ratio; QALY, quality-adjusted life-year.
* Percentage of QALY gain for the simulated scenario compared
with that obtained with the full-adherence scenario.
† Under full adherence, 7645 osteoporotic fractures would be pre-
vented. 95% CI are provided in parentheses.offset-time was related to time on therapy [44]. One potentialweakness of our analysis is that the impact of poor adherence
on fracture efficacy was not available in Ireland and was derived
from a large US study [10]. The impact of adherence on fracture
risk was however of the same magnitude as in many studies
[13]. In addition, for patients who restart therapy after a period
of interruption, the same adherence level was applied. Such
patients may however resume at a less adherent level, but this
would require further investigation.
Another potential limitation of this study is that using prescrip-
tion refill rates may overestimate medication adherence because it
assumes that patients take all the dispensed medications, but not
necessarily persistence. Prescription refill rates are, however, gener-
ally the onlyway to estimate adherence and represent a reliable and
inexpensive way of evaluating persistence and adherence [51]. An-
other reason for the underestimation of the burden of poor adher-
ence is the lack of inclusion of primary nonadherent patients. This
term refers to patients who never fill a prescription. These patients
were not included in the database because our study was based on
pharmacy records of filled prescriptions. In addition, ourmanuscript
deals primarily with direct costs. Decrease in medication adherence
reduces significantly medications effects and subsequently in-
creases the need for surgery. Lack of adherence and the subsequent
fracture increase also impact all health care resources utilization in-
cluding physiotherapy and occupational therapy. Caregiver costs as
well as loss of productivity and absenteeism were also shown to be
significant in osteoporosis management [52], and the lack of adher-
ence in osteoporosis medications may potentially result in overuti-
lization of pain medication, which can also be linked to decreased
productivity.
Another limitation is that highly adherent patientswill achieve
reductions in fracture risk based onmeta-analysis from published
clinical trials. This seems plausible because trials are likely to re-
flect the highest achievable rate of adherence in actual practice.
However, because adherence in all the trials (and not unique to
osteoporosis) is not optimal for all the patients, the efficacy from
these trials is likely to be reduced to some degree because of non-
adherence and nonpersistence. Therefore, we probably underes-
timated the true underlying risk reduction with therapy [53].
Another limitation is the use of a dichotomous measure for per-
sistence and adherence, which is likely to result in a loss of power
between patients who are fully nonadherent and those who are
just below the cutoff point for adherence.
0
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Fig. 3 – Cost-effectiveness (expressed in cost [in €] per
QALY gained) of adherence-enhancing interventions
according to their cost and effect on adherence. The cost-
effectiveness is graphically presented by the black lines,
and the gray lines represent the lower and upper limits of
the 95% confidence interval. QALY, quality-adjusted life-
year.
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611V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 0 4 – 6 1 2Finally, like all models, several limitations must be taken into
account. The most important are availability of data. Although
much of the data used to construct themodel were extracted from
the Irish data sets, some data were extrapolated from other coun-
tries, as was the case for the Belgian model [23]. In particular, the
impacts of fractures on health-related quality of life were gener-
ally derived from a Swedish study [35]. Although fracture disutility
ends to be similar between several countries [34], differencesmay
e present between Irish and Swedish patients. It could be argued
hat hip fractures are the fracture type considered to be the key
river in the cost-effectiveness of osteoporosis medications [54]
nd their incidence and costs were estimated from a local data-
ase. Potential limitations of the model have been previously ex-
ensively discussed [17,23]. In particular, the threshold for adher-
nce remains uncertain because there is no clinically meaningful
efinition for high adherence. Further studies should reexamine
he 0.8 threshold for adherence.
Generalizability of the results to thewhole populationmay also
e uncertain because adherence and persistence data were based
n a subpopulation in Ireland that is more socially deprived and
lderly. We do not, however, expect that adherence and persis-
ence data will substantially differ.
Our analysis may have important clinical and economic impli-
ations. First, it suggests that poor adherence can be considered as
he critical hurdle to osteoporosismanagement. Improving adher-
nce is therefore becoming urgent, but it remains a complex issue.
ehavioral programs to improve adherence with osteoporosis
edications have been initiated, but few interventions were effi-
acious, and no clear trends regarding successful intervention
echniques can be identified [21]. New formulations and longer
osage regimens have also been recently available, which in prin-
iple can help to improve adherence [55]. Less frequent dosing
egimens have been frequently associated with better adherence
56,57]. There is a need to conduct additional researchwith behav-
oral interventions and to consider the impact of specific pharma-
ological treatments on medication adherence. Because many
eterminants of poor adherence have been identified [58,59], un-
erstanding patients’ preferences for osteoporosis treatments and
nvolving patients into clinical decision making may certainly be
seful in optimizing treatment selection and in improving adher-
nce to therapy. Second, our analysis highlights the importance of
ntegrating medication adherence and persistence in pharmaco-
conomic analyses conducted in osteoporosis [26–28,30]. Poor ad-
erence represents a new perspective on health economic assess-
ent in osteoporosis [60], and our study may provide an
nteresting background for integrating medication adherence and
ersistence.
In summary, this analysis suggests that poor adherence with
steoporosis medications results in approximately a 50% reduc-
ion in the potential benefits observed in clinical trials and a dou-
ling of the cost per QALY gained from these medications. More-
ver, depending on their costs and outcomes, programs to
mprove adherence have the potential to be an efficient use of
esources.
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